Skin tolerability associated with transdermal drug delivery systems: An overview

Advances in Therapy

Volumn 26, Issue 10, 2009, Pages 920-935

  Ale, Iris ^a   Lachapelle, Jean Marie ^b   Maibach, Howard I ^c  

^a UNIVERSITY OF URUGUAY   (Uruguay)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Contact dermatitis; Skin reactions; Skin tolerability; Transdermal drug delivery; Transdermal patch

Indexed keywords

ANTIHISTAMINIC AGENT; CLONIDINE; CORTICOSTEROID; ESTRADIOL; FENTANYL; GLYCERYL TRINITRATE; LIDOCAINE; METHYLPHENIDATE; NICOTINE; OXYBUTYNIN; PLACEBO; RIVASTIGMINE; ROTIGOTINE; SCOPOLAMINE; SELEGILINE; TESTOSTERONE;

ACNE; ALZHEIMER DISEASE; APPLICATION SITE BURNING; APPLICATION SITE DERMATITIS; APPLICATION SITE DISCOLORATION; APPLICATION SITE ECZEMA; APPLICATION SITE EDEMA; APPLICATION SITE ERYTHEMA; APPLICATION SITE IRRITATION; APPLICATION SITE PAPULE; APPLICATION SITE PRURITUS; APPLICATION SITE RASH; APPLICATION SITE REACTION; APPLICATION SITE ULCER; APPLICATION SITE VESICLE; ATTENTION DEFICIT DISORDER; BLISTER; CLINICAL TRIAL; DEPIGMENTATION; DISEASE SEVERITY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; IRRITANT DERMATITIS; LOW DRUG DOSE; MAJOR DEPRESSION; OVERACTIVE BLADDER; PARKINSON DISEASE; PETECHIA; POSTHERPETIC NEURALGIA; REVIEW; RISK FACTOR; SIDE EFFECT; SKIN ALLERGY; SKIN BRUISING; SKIN EXFOLIATION; SKIN MANIFESTATION; SWEATING; TRANSDERMAL PATCH;

ADMINISTRATION, CUTANEOUS; AGE FACTORS; DERMATITIS, ALLERGIC CONTACT; DERMATITIS, IRRITANT; DRUG DELIVERY SYSTEMS; ERYTHEMA; HUMANS; PHARMACEUTICAL PREPARATIONS; RISK FACTORS; SEX FACTORS;

EID: 73949102378     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12325-009-0075-9     Document Type: Review

References (55)

1. Levin C, Maibach HI. Transdermal drug delivery system: an overview. In: Zhai H, Wilhelm K-P, Maibach HI, eds. Marzulli and Maibach's Dermato-toxicology. 7th edition. Boca Raton, FL: CRC Press; 2008:101-106.
2. J.D. Bos M.M. Meinardi 2000 The 500 Dalton rule for the skin penetration of chemical compounds and drugs Exp Dermatol 9 165 169 10.1034/j.1600-0625.2000. 009003165.x 1:CAS:528:DC%2BD3cXjvVWitLw%3D 10839713 (Pubitemid 30255378)
3. Y.N. Kalia R.H. Guy 2001 Modeling transdermal drug release Adv Drug Deliv Rev 48 159 172 10.1016/S0169-409X(01)00113-2 1:CAS:528:DC%2BD3MXjtlaqsrY%3D 11369080 (Pubitemid 32434401)
4. V.W. Nitti S. Sanders D.R. Staskin, et al. 2006 Transdermal delivery of drugs for urologic applications: basic principles and applications Urology 67 657 664 10.1016/j.urology.2005.11.039 16618554
5. R. Bernabei P. Martínez Lage 2008 Clinical benefits associated with a transdermal patch for dementia Eur Neurol Rev 3 10 13
6. Transderm Scop Patch (scopolamine 1.5 mg) [prescribing information]. Parsippany, NJ: Novartis. February 2006. Available at: http://www.transdermscop. com/prescribing-information.htm. Accessed October 2009.
7. Exelon Patch (rivastigmine transdermal system): How does the Exelon Patch work? Available at: http://www.exelonpatch.com/info/How-the-Exelon-Patch-Can- Help/How-exelon-patch-works.jsp. Accessed April 2009.
8. M. Murphy A.J. Carmichael 2000 Transdermal drug delivery systems and skin sensitivity reactions. Incidence and management Am J Clin Dermatol 1 361 368 10.2165/00128071-200001060-00004 1:STN:280:DC%2BD3MnltVejtg%3D%3D 11702612
9. M.R. Holdiness 1989 A review of contact dermatitis associated with transdermal therapeutic systems Contact Dermatitis 20 3 9 10.1111/j.1600-0536. 1989.tb03087.x 1:STN:280:DyaL1M7itVSrtA%3D%3D 2492460 (Pubitemid 19028518)
10. D.J. Hogan H.I. Maibach 1990 Adverse dermatologic reactions to transdermal drug delivery systems J Am Acad Dermatol 22 811 814 10.1016/0190-9622(90)70113-V 1:STN:280:DyaK3c3ntVGisw%3D%3D 2112162
11. L. Priano M.R. Gasco A. Mauro 2006 Transdermal treatment options for neurological disorders: impact on the elderly Drugs Aging 23 357 375 10.2165/00002512-200623050-00001 1:CAS:528:DC%2BD28Xptlaqsrg%3D 16823990 (Pubitemid 44050424)
12. B.W. Barry 2001 Novel mechanisms and devices to enable successful transdermal drug delivery Eur J Pharm Sci 14 101 114 10.1016/S0928-0987(01) 00167-1 1:CAS:528:DC%2BD3MXlslGnsLY%3D 11500256 (Pubitemid 32737532)
13. B.S. Galer M.C. Rowbotham J. Perander E. Friedman 1999 Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study Pain 80 533 538 10.1016/S0304-3959(98)00244-9 1:CAS:528:DyaK1MXjsFynu7s%3D 10342414 (Pubitemid 29182702)
14. R.L. Findling O.G. Bukstein R.D. Melmed, et al. 2008 A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit/hyperactivity disorder J Clin Psychiatry 69 149 159 10.4088/JCP.v69n0120 1:CAS:528: DC%2BD1cXivVOksL8%3D 18312050
15. R. Cartwright L. Cardozo 2007 Transdermal oxybutynin: sticking to the facts Eur Urol 51 907 914 10.1016/j.eururo.2006.11.033 1:CAS:528: DC%2BD2sXks1Git78%3D 17157979 (Pubitemid 46281437)
16. R.L. Watts J. Jankovic C. Waters A. Rajput B. Boroojerdi J. Rao 2007 Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease Neurology 68 272 276 10.1212/01.wnl.0000252355.79284.22 1:CAS:528:DC%2BD2sXlt12msg%3D%3D 17202432 (Pubitemid 46148338)
17. R. Schmidt C. Alf C. Bancher, et al. 2009 Transdermal rivastigmine patch in outpatient services in Austria: a naturalistic study in 103 patients with Alzheimer dementia Neuropsychiatry 23 58 63
18. J.A. Bodkin J.D. Amsterdam 2002 Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients Am J Psychiatry 159 1869 1875 10.1176/appi.ajp.159.11.1869 12411221 (Pubitemid 35283252)
19. Marzulli FN, Maibach HI. Allergic contact dermatitis. In: Zhai H, Wilhelm K-P, Maibach HI, eds. Marzulli and Maibach's Dermatotoxicology. 7th edition. Boca Raton, FL: CRC Press; 2008:155-158.
20. Weltfriend S, Maibach HI. Irritant dermatitis: clinical heterogeneity and contributing factors. In: Zhai H, Wilhelm K-P, Maibach HI, eds. Marzulli and Maibach's Dermatotoxicology. 7th edition. Boca Raton, FL: CRC Press; 2008:125-138.
21. Lachapelle JM, Maibach HI. Patch Testing and Prick Testing. A Practical Guide. 2nd edition. Berlin Heidelberg: Springer; 2009.
22. Moulton-Levy NM, Maibach HI. Photoirritation (phototoxicity, phototoxic dermatitis). In: Zhai H, Wilhelm K-P, Maibach HI, eds. Marzulli and Maibach's Dermatotoxicology. 7th edition. Boca Raton: CRC Press; 2008:209-214.
23. Lidoderm (lidocaine patch 5%) [prescribing information]. Chadds Ford, PA; Endo Pharmaceuticals, Inc. February 2008. Available at: http://www.lido-derm. com/prescrib.aspx. Accessed April 2009.
24. W.E. Pelham Jr. M.J. Manos C.E. Ezzell, et al. 2005 A doseranging study of a methylphenidate transdermal system in children with ADHD J Am Acad Child Adolesc Psychiatry 44 522 529 10.1097/01.chi.0000157548.48960.95 15908834 (Pubitemid 40720951)
25. Daytrana (methylphenidate transdermal system) [prescribing information]. Wayne, PA: Shire US Inc. January 2008. Available at: http://www.daytrana.com/ prescribing-information. Accessed April 2009.
26. R.R. Dmochowski P.K. Sand N.R. Zinner M.C. Gittelman G.W. Davila S.W. Sanders 2003 Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence Urology 62 237 242 10.1016/S0090-4295(03)00356-X 12893326 (Pubitemid 36952069)
27. R.R. Dmochowski G.W. Davila N.R. Zinner, et al. 2002 Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence J Urol 168 580 586 10.1016/S0022-5347(05)64684-8 1:CAS:528:DC%2BD38XmtFWhtbo%3D 12131314
28. Oxytrol patch (oxybutynin transdermal system) [prescribing information]. Corona, CA: Watson Pharmaceuticals, Inc. May 2006. Available at: http://pi.watson.com/data
29. P.A. LeWitt K.E. Lyons R. Pahwa 2007 Advanced Parkinson disease treated with rotigotine transdermal system: PREFER study Neurology 68 1262 1267 10.1212/01.wnl.0000259516.61938.bb 1:CAS:528:DC%2BD2sXktFOntLg%3D 17438216 (Pubitemid 46625971)
30. N. Giladi B. Boroojerdi A.D. Korczyn D.J. Burn C.E. Clarke A.H. Schapira 2007 Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole Mov Disord 22 2398 2404 10.1002/mds.21741 17935234 (Pubitemid 351155987)
31. Neupro (rotigotine transdermal system) [prescribing information]. Mequon, WI: Schwarz Pharma, LLC. June 2006. Available at: http://www.neupro.com/ documents/Neupro+PI-071207.pdf. Accessed April 2009.
32. C.H. Sadowsky A. Dengiz J.T. Olin B. Koumaras X. Meng S. Brannan 2009 Switching from donepezil tablets to rivastigmine transdermal patch in Alzheimer's disease Am J Alzheimers Dis Other Demen 24 267 275 10.1177/1533317509333037 19293130
33. B. Winblad J. Cummings N. Andreasen, et al. 2007 A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease - rivastigmine patch versus capsule Int J Geriatr Psychiatry 22 456 467 10.1002/gps.1788 17380489 (Pubitemid 46831690)
34. D.S. Robinson J.D. Amsterdam 2008 The selegiline transdermal system in major depressive disorder: a systematic review of safety and tolerability J Affect Disord 105 15 23 10.1016/j.jad.2007.04.024 1:CAS:528:DC%2BD2sXhsVelt7zN 17568687 (Pubitemid 350236356)
35. J.D. Amsterdam J.A. Bodkin 2006 Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial J Clin Psychopharmacol 26 579 586 10.1097/01.jcp.0000239794.37073.70 1:CAS:528:DC%2BD28Xht1Smt7jJ 17110814 (Pubitemid 44772734)
36. Emsam (selegiline transdermal system) [prescribing information]. Princeton, NJ: Bristol Myers Squibb. February 2008. Available at: http://packageinserts.bms.com/pi/pi-emsam.pdf. Accessed April, 2009.
37. C.G. Mathias H.I. Maibach 1978 Dermatotoxicology monographs I. Cutaneous irritation: factors infuencing the response to irritants Clin Toxicol 13 333 346 10.3109/15563657808988241 1:STN:280:DyaE1M7is1CqtA%3D%3D 369770
38. Chew A-L, Maibach HI. Classification of irritant dermatitis. In: Zhai H, Wilhelm K-P, Maibach HI, eds. Marzulli and Maibach's Dermatotoxicology. 7th edition. Boca Raton, FL: CRC Press; 2008:923-926.
39. A.A. Fisher 1984 Dermatitis due to transdermal therapeutic systems Cutis 34 526 531 1:STN:280:DyaL2M7gtVChsg%3D%3D 6240373
40. J.F. Hurkmans H.E. Bodde L.M. Van Driel H. Van Doorne H.E. Junginger 1985 Skin irritation caused by transdermal drug delivery systems during long-term (5 days) application Br J Dermatol 112 461 467 10.1111/j.1365-2133.1985.tb02321.x 1:STN:280:DyaL2M7pvFKksA%3D%3D 3994921 (Pubitemid 15148492)
41. J.P. Thyssen H.I. Maibach 2008 Drug-elicited systemic allergic (contact) dermatitis - update and possible pathomechanisms Contact Dermatitis 59 195 202 1:CAS:528:DC%2BD1cXhtlaitr3L 18844694
42. S. Patil H.I. Maibach 1994 Effect of age and sex on the elicitation of irritant contact dermatitis Contact Dermatitis 30 257 264 10.1111/j.1600-0536. 1994.tb00594.x 1:STN:280:DyaK2cznsVWntA%3D%3D 8088137 (Pubitemid 24156846)
43. J.M. Waller H.I. Maibach 2005 Age and skin structure and function, a quantitative approach (I): blood flow, pH, thickness, and ultrasound echogenicity Skin Res Technol 11 221 235 10.1111/j.0909-725X.2005.00151.x 16221138 (Pubitemid 41614679)
44. J.M. Waller H.I. Maibach 2006 Age and skin structure and function, a quantitative approach (II): protein, glycosaminoglycan, water, and lipid content and structure Skin Res Technol 12 145 154 10.1111/j.0909-752X.2006.00146.x 16827688 (Pubitemid 43985007)
45. C. Kwangsukstith H.I. Maibach 1995 Effect of age and sex on the induction and elicitation of allergic contact dermatitis Contact Dermatitis 33 289 298 10.1111/j.1600-0536.1995.tb02041.x 1:STN:280:DyaK287ls1eqtg%3D%3D 8565482
46. M.H. Allen S.H. Wakelin D. Holloway, et al. 2000 Association of TNFA gene polymorphism at position -308 with susceptibility to irritant contact dermatitis Immunogenetics 51 201 205 10.1007/s002510050032 1:CAS:528: DC%2BD3cXht1KgsbY%3D 10752629
47. D.J. Gawkrodger J.P. Vestey W.K. Wong P.K. Buxton 1986 Contact clinic survey of nickel-sensitive subjects Contact Dermatitis 14 165 169 10.1111/j.1600-0536.1986.tb01198.x 1:STN:280:DyaL283hvFamuw%3D%3D 2940060
48. H. Zhai H.I. Maibach 2001 Skin occlusion and irritant and allergic contact dermatitis: an overview Contact Dermatitis 44 201 206 10.1034/j.1600-0536.2001.044004201.x 1:CAS:528:DC%2BD3MXivFCntb0%3D 11260234 (Pubitemid 32234753)
49. Okoro A, Rook AJ, Canizares O. Chapter 23. Eczemas in the tropics. Plant dermatitis. In: Canizares O, Harman R, eds. Clinical Tropical Dermatology. 2nd edition. Boston, MA: Blackwell Scientific Publications; 1992:449-481.
50. G. Lefèvre G. Sedek H.L. Huang, et al. 2007 Pharmaco-kinetics of a rivastigmine transdermal patch formulation in healthy volunteers: relative effects of body site application J Clin Pharmacol 47 471 478 10.1177/0091270006297748 17389556 (Pubitemid 46465956)
51. C. Nieboer D.P. Bruynzeel D.M. Boorsma 1987 The effect of occlusion of the skin with transdermal therapeutic system on Langerhans' cells and the induction of skin irritation Arch Dermatol 123 1499 1502 10.1001/archderm.123. 11.1499 1:STN:280:DyaL1c%2FkvVCjuw%3D%3D 2960271 (Pubitemid 17153223)
52. E. Held T. Agner 2001 Effect of moisturizers on skin susceptibility to irritants Acta Derm Venereol 81 104 107 10.1080/00015550152384227 1:CAS:528:DC%2BD3MXnsFGnu74%3D 11501645 (Pubitemid 32662149)
53. E. Held H. Lund T. Agner 2001 Effect of different moisturizers on SLS-irritated human skin Contact Dermatitis 44 229 234 10.1034/j.1600-0536.2001. 044004229.x 1:CAS:528:DC%2BD3MXivFCntbY%3D 11260239 (Pubitemid 32234758)
54. L. Kynemund Pedersen T. Agner E. Held J.D. Johansen 2004 Methyldibromoglutaronitrile in leave-on products elicits contact allergy at low concentration Br J Dermatol 151 817 822 10.1111/j.1365-2133.2004.06145.x 1:STN:280:DC%2BD2critVOqtA%3D%3D 15491422 (Pubitemid 39482115)
55. A.A. Amkraut W.P. Jordan L. Taskovich 1996 Effect of coadministration of corticosteroids on the development of contact sensitization J Am Acad Dermatol 35 27 31 10.1016/S0190-9622(96)90491-0 1:STN:280:DyaK283nt12lsA%3D%3D 8682959 (Pubitemid 26231318)